Abraham Bisrat K, Vogler Mary, Talati Achala, Suresh Prapitha, Gill Balwant, Ravikumar Saiganesh, Shepard Colin, Gulick Roy, Nash Denis, Peters Vicki
Bureau of HIV, New York City Department of Health of Mental Hygiene, New York City, NY.
Division of Infectious Diseases, Weill Cornell Medicine, New York City, NY.
J Acquir Immune Defic Syndr. 2025 Jan 1;98(1):20-28. doi: 10.1097/QAI.0000000000003535.
Maternal and pregnancy outcomes among women with perinatally acquired HIV (PHIV) versus women with HIV acquired through other routes (NPHIV) are not fully understood.
US-born women during 2005-2015 in New York City.
We used data from the New York City HIV surveillance registry, Expanded Perinatal Surveillance database, and Vital Statistics, to compare pregnancy and all-cause mortality outcomes among women with PHIV versus NPHIV delivering infants during 2005-2015.
There were 186 deliveries among 137 women with PHIV and 1188 deliveries among 910 women with NPHIV. Women with PHIV were younger at delivery, more likely to be aware of their HIV status, and less likely to use substances or be incarcerated. At the time of delivery, women with PHIV were more likely to have HIV RNA >1000 copies/mL (34% vs. 19%), CD4 <200 cells/µL (18% vs. 7%; median CD4 300 cells/µL vs. 435 cells/µL), to have adequate prenatal care (43% vs. 35%), and to deliver by elective C-section (63% vs. 49%). There were no differences in intrapartum and neonatal antiretroviral therapy use, perinatal transmission, gestational age, and birth weight of the infants, nor infant mortality. Women with NPHIV had higher survival than women with PHIV (RR = 2.29, P = 0.004; age-adjusted risk ratio = 3.23, P < 0.001; age and CD4 adjusted risk ratio = 2.09, P = 0.046).
Women with PHIV had lower long-term survival after delivery likely because of limited HIV treatment options in childhood and a longer duration of HIV infection, underscoring the importance of close follow-up and tailored support services beyond the postpartum period.
围产期感染艾滋病毒(PHIV)的女性与通过其他途径感染艾滋病毒(NPHIV)的女性的孕产妇及妊娠结局尚未完全明确。
2005年至2015年期间出生于美国纽约市的女性。
我们使用了纽约市艾滋病毒监测登记处、围产期扩大监测数据库和生命统计数据,比较2005年至2015年期间分娩婴儿的PHIV女性与NPHIV女性的妊娠结局和全因死亡率。
137名PHIV女性中有186例分娩,910名NPHIV女性中有1188例分娩。PHIV女性分娩时年龄更小,更有可能知晓自己的艾滋病毒感染状况,使用毒品或被监禁的可能性更小。分娩时,PHIV女性更有可能出现艾滋病毒RNA>1000拷贝/毫升(34%对19%)、CD4<200细胞/微升(18%对7%;CD4中位数300细胞/微升对435细胞/微升),接受充分的产前护理(43%对35%),并通过择期剖宫产分娩(63%对49%)。在产时和新生儿抗逆转录病毒治疗的使用、围产期传播、孕周、婴儿出生体重以及婴儿死亡率方面没有差异。NPHIV女性的生存率高于PHIV女性(相对风险=2.29,P=0.004;年龄调整风险比=3.23,P<0.001;年龄和CD4调整风险比=2.09,P=0.046)。
PHIV女性分娩后的长期生存率较低,可能是因为儿童期艾滋病毒治疗选择有限以及艾滋病毒感染持续时间较长,这凸显了产后密切随访和量身定制支持服务的重要性。